Market revenue in 2023 | USD 90.1 million |
Market revenue in 2030 | USD 144.3 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.29% in 2023. Horizon Databook has segmented the Europe cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Similar to North America, Europe has established regulatory frameworks to help in the development and marketing of cell and gene therapies. Regulatory agencies, such as the European Medicines Agency (EMA), offer possibilities for fast approval and limited marketing authorization for novel therapies.
This favorable regulatory environment promotes investment and innovation in the field of cell & gene therapies. The EMA, the medical regulatory body for the European Union, has been a global leader in evaluating advanced therapy medicinal products, a class of novel biological products that include gene therapy.
In 2009, the EMA approved a tissue-engineering product, 1 year ahead of the U.S. to approve its first ATMP. It also approved the world's first gene therapy in 2012. Advanced therapy medicinal products are divided into three main categories: somatic Cell Therapy Medicinal Products (sCTMPs), Gene Therapy Medicinal Products (GTMPs), and Tissue-Engineered Products (TEPs).
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This continent databook contains high-level insights into Europe cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account